Inogen (NASDAQ:INGN) Stock Crosses Below 200 Day Moving Average – Should You Sell?

Inogen, Inc (NASDAQ:INGN)’s share price passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $6.38 and traded as low as $6.33. Inogen shares last traded at $6.42, with a volume of 134,787 shares changing hands.

Analyst Upgrades and Downgrades

INGN has been the topic of several research reports. Freedom Capital raised shares of Inogen to a “strong-buy” rating in a research report on Tuesday, April 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Inogen in a report on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy”.

Inogen Stock Down 0.2%

The company’s fifty day moving average price is $6.46 and its two-hundred day moving average price is $6.38. The firm has a market cap of $173.85 million, a PE ratio of -7.05 and a beta of 1.58.

Inogen (NASDAQ:INGN) last announced its quarterly earnings data on Thursday, May 7th. The medical technology company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.06). Inogen had a negative net margin of 7.08% and a negative return on equity of 12.90%. The firm had revenue of $85.11 million during the quarter, compared to analyst estimates of $82.35 million. As a group, analysts predict that Inogen, Inc will post -0.77 earnings per share for the current year.

Insider Buying and Selling at Inogen

In related news, EVP Boyer Jennifer M. Yi sold 10,938 shares of the company’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $6.60, for a total transaction of $72,190.80. Following the transaction, the executive vice president owned 5,039 shares of the company’s stock, valued at $33,257.40. This represents a 68.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 2.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Inogen

A number of large investors have recently made changes to their positions in INGN. Marquette Asset Management LLC acquired a new position in Inogen during the second quarter worth about $228,000. Assenagon Asset Management S.A. lifted its position in shares of Inogen by 70.4% during the 2nd quarter. Assenagon Asset Management S.A. now owns 86,940 shares of the medical technology company’s stock valued at $561,000 after acquiring an additional 35,912 shares during the period. Quantinno Capital Management LP boosted its stake in shares of Inogen by 78.1% during the 1st quarter. Quantinno Capital Management LP now owns 90,995 shares of the medical technology company’s stock worth $562,000 after acquiring an additional 39,915 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its stake in shares of Inogen by 203.9% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 586,159 shares of the medical technology company’s stock worth $3,622,000 after acquiring an additional 393,310 shares in the last quarter. Finally, Hsbc Holdings PLC grew its holdings in shares of Inogen by 75.4% in the 4th quarter. Hsbc Holdings PLC now owns 60,482 shares of the medical technology company’s stock worth $406,000 after acquiring an additional 25,998 shares during the period. Hedge funds and other institutional investors own 89.94% of the company’s stock.

Inogen Company Profile

Inogen, Inc (NASDAQ: INGN) is a medical device company specializing in the development, manufacture and marketing of innovative oxygen therapy solutions. The company’s core focus is on portable oxygen concentrators (POCs) designed to support patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen’s offerings aim to provide users with mobility and independence by reducing reliance on traditional compressed-gas cylinders and enabling oxygen therapy on the go.

Inogen’s flagship product line, including the Inogen One family of portable oxygen concentrators, leverages proprietary flow technology to deliver continuous and pulse-dose oxygen.